相关实验视频

Updated: May 13, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

作为替代终点,临床上有意义的eGFR斜率在CKD阶段和斜率评估期之间存在差异:CKD-JAC研究

Takahiro Imaizumi^1,2, Hirotaka Komaba³, Takayuki Hamano^4,5

¹Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.

Clinical kidney journal

|February 14, 2025

概括

估计较慢的膜过率 (eGFR) 降低预测慢性病 (CKD) 患者的功能衰竭风险较低. 这一发现支持eGFR斜率作为替代终点,即使在晚期CKD阶段.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
临床试验临床试验
生物统计学生物统计学

背景情况:

估计的淋巴膜过率 (eGFR) 斜率显示为慢性病 (CKD) 进展的替代终点具有前途.
现有证据主要集中在早期CKD (1-3阶段) 的西方人群中.
缺乏对eGFR斜率预测值的正式阶段分析.

研究的目的:

在亚洲人群中评估EGFR斜率与功能衰竭风险在CKD所有阶段之间的关联.
确定评估eGFR斜率作为替代终点的最佳评估期.
提供关于eGFR斜率在高级CKD临床试验设计中的实用性的证据.

主要方法:

分析了来自慢性病日本队列研究的数据,包括患有晚期慢性病 (4和5阶段) 的患者.
使用混合效应模型,对0.5年,1年和2年的eGFR斜率的估计.
检查eGFR斜率与随后的替代疗法启动之间的关联.

主要成果:

较慢的eGFR下降显着与所有CKD阶段的功能衰竭风险降低有关.
在晚期CKD阶段 (3, 4, 5) 中,eGFR斜率的预测能力更为明显.
在1年内,EGFR的1.91毫升/分钟/1.73米2/年减速相当于3期CKD中功能衰竭风险降低了20%.

结论:

亚洲人口中不同阶段的CKD进展的eGFR斜率是一个有效的替代终点.
较短的评估期 (不到2年) 可能是可行的,以评估晚期CKD的eGFR斜率.
这些发现支持在临床试验中使用eGFR斜率,特别是对于晚期CKD患者.

关键词:

慢性脏疾病慢性脏疾病临床流行病学临床流行病学在eGFR的斜坡.功能衰竭功能衰竭是什么?替代终点替代终点

更多相关视频

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
The pKa of a drug,...

Determination of Renal Drug Clearance: Graphical and Midpoint Methods

Determination of Renal Drug Clearance: Graphical and Midpoint Methods

Renal clearance, a crucial parameter in pharmacokinetics, can be determined using two different methods: the graphical method and the midpoint method. These methods provide insights into the rate of drug excretion by the kidneys and aid in assessing renal function.
The graphical method involves plotting the rate of drug excretion in urine against the plasma drug concentration. By analyzing the graph, the clearance can be calculated and obtained. Drugs rapidly excreted by the kidneys exhibit a...

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...